Cookie Consent by Free Privacy Policy website Masimo and Philips licensing agreement brings Masimo NomoLine Capnography and O3 Regional Oximetry to select Philips patient monitors
may 27, 2020 - Philips

Masimo and Philips licensing agreement brings Masimo NomoLine Capnography and O3 Regional Oximetry to select Philips patient monitors

Masimo and Royal #philips, both global leaders in patient monitoring, announced today that they have reinforced their partnership, whereby #philips will integrate additional Masimo measurement technologies into select IntelliVue® MX-series multi-parameter monitors, to help clinicians assess cerebral oximetry and ventilation status.

Core Masimo noninvasive measurements, such as SET® Measure-through Motion and Low Perfusion™ pulse oximetry and advanced rainbow SET® Pulse CO-Oximetry parameters like noninvasive hemoglobin (SpHb®), have long been available on a wide range of #philips multi-parameter monitors.

In 2016, Masimo and #philips entered into a multi-year business partnership involving both companies’ innovations in patient monitoring and therapy solutions. Now, in 2020, #philips becomes one of Masimo’s first industry partners to launch additional advanced Masimo measurements, NomoLine and O3, in their own patient monitors, sharing Masimo’s expertise in capnography and regional cerebral oximetry with caregivers and patients around the world.

As global leader in #health technology, we are delighted to reinforce our partnership with Masimo, bringing their advanced measurements to our innovative IntelliVue patient monitors, thereby making them even more versatile.
Frans van Houten

CEO of Royal #philips.

NomoLine capnography and O3 regional oximetry measurements are available now on #philips MX500 and MX550 monitors [1] in select markets [2] throughout the world, and are also available directly from Masimo on its Root® Patient Monitoring and Connectivity Platform and when connected to select #philips patient monitors via Philips’ IntelliBridge module:

NomoLine “no-moisture” sampling lines are designed for low-flow applications and can be used in a variety of clinical scenarios and care settings, on both intubated and non-intubated patients of all ages, in both low- and high-humidity applications.
O3 regional oximetry may help clinicians monitor cerebral oxygenation in situations in which pulse oximetry alone may not be fully indicative of the oxygen in the brain.

“As global leader in #health technology, we are delighted to reinforce our partnership with Masimo, bringing their advanced measurements to our innovative IntelliVue patient monitors, thereby making them even more versatile,” said Frans van Houten, CEO of Royal #philips. “Our customers expect integrated solutions to help them address the quadruple aim of healthcare. The complementary strengths of #philips and Masimo allow us to offer, reliable ventilation and regional oximetry solutions, which we expect will help clinicians deliver even better patient care.”

“Combining our expertise in noninvasive monitoring and signal processing technologies with Philips’ expertise in integrated patient monitoring and therapy solutions is a win-win for patients and clinicians alike,” said Joe Kiani, Founder and CEO of Masimo. “We are proud that #philips, recognizing our expertise in this clinical space, has chosen to make our innovative O3 and NomoLine platforms available to their customers. We look forward to continuing our partnership with a focus on improving patient outcomes and reducing the cost of care.”

You might be interested in

february 20, 2024
february 07, 2024
january 31, 2024

1.88 billion lives improved by Philips’ health technology products and services; on track to improve 2 billion lives by 2025 Throu...

 FDA 510(k) clearance of latest Philips IntelliVue patient monitor software helps drive alarm management strategies toward a more ...

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that its latest TEE transducer, design...